Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. (Q33412557)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Paul C. Boutros

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

12

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Mun Sem Liew

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Maud H W Starmans

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Ali Tafreshi

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Sam Harris

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Malcolm Feigen

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Shane White

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Allan Zimet

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Philippe Lambin

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Paul Mitchell

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

0 references

publication date

16 October 2013

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Cancer Medicine

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

916-924

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Influence of Comorbidities on the Efficacy of Radiotherapy with or without Chemotherapy in Elderly Stage III Non-small Cell Lung Cancer Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Challenges scoring radiation pneumonitis in patients irradiated for lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Concurrent chemoradiotherapy in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Epidermal growth factor receptor mutations in lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3892396

21 June 2018

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCAM4.142

21 January 2018

Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging developments of chemoradiotherapy in stage III NSCLC

1 reference

https://pubmed.ncbi.nlm.nih.gov/24403265

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CAM4.142

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24403265%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33412557&oldid=1641885818"